Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen

Abstract

Objectives In this communication we report an important findings, the effect of Al/Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen when administered concomitantly.

Methods Subjects were divided into four groups, each containing 6 subjects, to evaluate the effect of antacid and food on pharmacokinetic of dexibuprofen. A new HPLC method was developed and validated for plasma sample analysis. Mobile phase was comprised of Acetonitrile: Methanol: 0.05M Phosphate buffer (40:10:50), pH was adjusted to 6.85±0.01 with NaOH. Mobile phase was eluted through C18-ODS column and drug was detected at 223 nm. Plasma was obtained and stored at − 70°C until analysis. Drug was extracted from each plasma sample of volunteer and quantified by using HPLC technique.

Results A decrease in dexibuprofen absorption was observed in Test Group-1 when administered with Antacid as compared to Controlled Group-1. Mean C_max values showed a significant (p value 0.035) decrease from 44.14±2.3 to 33.1±0.8 μg/mL. T_max, Area under curve, t_1/2, Cl, V_d and K_e were not affected significantly. AUC increased from 195.7±8.9 μg.hr/mL to 222.8±14.7 μg.hr/mL. In contrast, test Group-2 showed an increase in dexibuprofen absorption. t_1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas K_e reduced from 0.159±0.00 to 0.116±0.006 hrs^-1. C_max increased from 44.877±2.263 to 51.721±0.096 μg/mL.

Conclusion It is concluded that concomitant intake of Al/Mg hydroxide antacid or food with dexibuprofen has an impact to significantly alter its pharmacokinetic parameters.

Key words

dexibuprofen - pharmacokinetic - drug-Interaction - HPLC

• References

• 1 Vane J. The fight against rheumatism: From willow bark to COX-1 sparing drugs. Journal of Physiology and Pharmacology 2000; 51: 4, 1
• 2 El Sayed MT. et al. Design, synthesis, anti-inflammatory activity and molecular docking of potential novel antipyrine and pyrazolone analogs as cyclooxygenase enzyme (COX) inhibitors. Bioorganic & Medicinal Chemistry Letters 2018; 28 p 952-957
• 3 Matthews ML, Melika R, Murray Y. Nonopioid and Adjuvant Analgesics for Acute Pain Management, in Clinical Approaches to Hospital Medicine. 2018. Springer; p 225-241
• 4 Kaufman DW. et al. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiology and drug safety. 2018
• 5 Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. American Journal of Therapeutics 2000; 7 p 115-122
• 6 Bacchi S. et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents) 2012; 11 p 52-64
• 7 Conaghan PG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International 2012; 32 p 1491-1502
• 8 McCAFFERY M. Newer uses of NSAIDs. AJN The American Journal of Nursing 1985; 85 p 781
• 9 Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Safety 2001; 24 p 715-725
• 10 Qian Y. et al. A computerized system for detecting signals due to drug–drug interactions in spontaneous reporting systems. British Journal of Clinical Pharmacology 2010; 69 p 67-73
• 11 McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. The American Journal on Addictions 2010; 19 p 4-16
• 12 Kaehler S, Phleps W, Hesse E. Dexibuprofen: pharmacology, therapeutic uses and safety. Inflammopharmacology 2003; 11 p 371-383
• 13 Zohmann A. et al. S (+)-ibuprofen (dexibuprofen)—Excellent tolerance has not to be combined with poor clinical efficacy. Inflammopharmacology 1998; 6 p 75-79
• 14 Björkman R. et al. Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat. Journal of Clinical Pharmacology 1996; 36(12 Suppl) p 20S-26S
• 15 Somogyi A, Bochner F, Foster D. Inside the isomers: The tale of chiral switches. Australian Prescriber 2004; 27: 2
• 16 Kumaresan C. Ibuprofen (Dexibuprofen): The superior non-steroidal anti-inflammatory agents for development of pharmaceuticals. Int J Curr Pharm Res 2010; 2 p 1-3
• 17 Parr AF. et al. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er-labeled sustained-release tablets. Pharmaceutical Research 1987; 4 p 486-489
• 18 Tsume Y. et al. The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. European Journal of Pharmaceutical Sciences 2014; 57 p 152-163
• 19 Amidon GL. et al. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 1995; 12 p 413-420
• 20 Antal E. et al. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. The Journal of Clinical Pharmacology 1986; 26 p 184-190
• 21 Furst DE, Ulrich RW, Varkey-Altamirano C. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, and drugs used in gout. Basic and Clinical Pharmacology 2001; 11 p 621-642
• 22 Wagner W, Khanna P, Furst D. Non-steroidal-anti inflammatory drugs, disease modifying anti rheumatic drugs, non opioid analgesics and drugs used in Gout. Basic and Clinical Pharmacology. 9^th ed. McGraw hill Booston; 2004: 585
• 23 Olive G. [Analgesic/Antipyretic treatment: ibuprofen or acetaminophen? An update]. Therapie 2005; 61 p 151-160
• 24 Insel PA. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. The Pharmacological Basis of Therapeutics 1996; 9 p 617-657
• 25 Bonabello A. et al. Dexibuprofen (S (+)-isomer ibuprofen) reduces gastric damage and improves analgesic and antiinflammatory effects in rodents. Anesthesia & Analgesia 2003; 97 p 402-408
• 26 CDER F. Guidance for Industry: Food-effect bioavailability and fed bioequivalence studies. 2002
• 27 Mandai U. et al. Bioequivalence study of two formulations containing 400 mg dexibuprofen in healthy Indian subjects. Arzneimittelforschung 2008; 58 p 342-347
• 28 Loya P, Saraf MN. A simple HPLC-UV method development and validation for the quantification of dexibuprofen applied in bioequivalence study. Journal of Liquid Chromatography & Related Technologies 2012; 35 p 1798-1811
• 29 Gabard B. et al. Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. European Journal of Clinical Pharmacology 1995; 48 p 505-511
• 30 Hurwitz A. Antacid therapy and drug kinetics. Clinical pharmacokinetics 1977; 2 p 269-280
• 31 Neuvonen P, Kivistö K. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. European Journal of Clinical Pharmacology 1988; 35 p 495-501
• 32 Tobert J. et al. Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clinical Pharmacology & Therapeutics 1981; 30 p 385-389
• 33 Sadowski DC. Drug interactions with antacids. Drug Safety 1994; 11 p 395-407
• 34 Gontarz N. et al. Effect of antacid suspension on the pharmacokinetics of ibuprofen. Clinical Pharmacy 1987; 6 p 413-416
• 35 Ravic M, Johnston A, Turner P. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgraduate Medical Journal 1989; 66 p S30-S34
• 36 Dittrich P. et al. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs under Experimental and Clinical Research 1989; 16 p 57-62
• 37 Wills RJ. et al. The effect of food and antacid on the absorption of fendosal. Biopharmaceutics & Drug Disposition 1985; 6 p 43-50
• 38 Nail SL, White JL, Hem SL. Structure of aluminum hydroxide gel I: Initial precipitate. Journal of Pharmaceutical Sciences 1976; 65 p 1188-1191
• 39 Forth W, Rummel W. Pharmacology of intestinal absorption: Gastrointestinal absorption of drugs. Volumes 1 and 2. 1975. Pergamon Press Ltd;
• 40 McElnay J, Dʼarcy P. Sites and mechanisms of drug interactions I. In vitro, intestinal and metabolic interactions. International Journal of Pharmaceutics 1980; 5 p 167-185
• 41 Charman WN. et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. Journal of Pharmaceutical Sciences 1997; 86 p 269-282
• 42 Benet LZ. et al. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. Goodman and Gilmanʼs the Pharmacological Basis of Therapeutics 1996; p 3-27
• 43 Prescott L. Gastric emptying and drug absorption. British Journal of Clinical Pharmacology 1974; 1 p 189-190
• 44 Rehnasalim, et al. Biowaver monographs of dexibuprofen. International Journal of Pharmaceutical, Chemical and Biological Sciences 2013; 3 p 12
• 45 Rostami-Hodjegan A. et al. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. I. A four-way crossover study to compare the concentration–time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Development and Industrial Pharmacy 2002; 28 p 523-531
• 46 Neuvonen PJ. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. British Journal of Clinical Pharmacology 1991; 31 p 263-266
• 47 Udaykumar P. Short textbook of pharmacology for dental and allied health sciences. 2008. Jaypee Brothers Publishers;
• 48 Tripathi K. Essentials of Medical Pharmacology. 2013 JP Medical Ltd.
• 49 Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Journal of Pharmaceutical Sciences 1996; 85 p 525-529
• 50 Olanoff LS. et al. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clinical Pharmacology & Therapeutics 1986; 40 p 408-414
• 51 Marasanapalle VP, Li X, Jasti BR. Effects of food on drug absorption. Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications 2011; p 221-231
• 52 Fleisher D. et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical Pharmacokinetics 1999; 36 p 233-254
• 53 Ungethum W. Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. Arzneimittel-Forschung 1991; 41 p 797-800
• 54 Marathe P. et al. Evaluation of the effect of food on the pharmacokinetics of avitriptan. Biopharmaceutics & Drug Disposition 1998; 19 p 381-394
• 55 Miles C. et al. CCK antagonist pre-treatment inhibits meal-enhanced drug absorption in dogs. Regulatory Peptides 1997; 68 p 9-14
• 56 Dressman JB. et al. Absorption of flurbiprofen in the fed and fasted states. Pharmaceutical Research 1992; 9 p 901-907
• 57 Horter D, Dressman J. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery reviews 2001; 46 p 75-87
• 58 Drabant S. et al. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58 p 689-695
• 59 Welling PG. Effects of food on drug absorption. Annual Review of Nutrition 1996; 16 p 383-415